---
title: "MLTX.US (MLTX.US) — 相關新聞"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/MLTX.US/news.md"
symbol: "MLTX.US"
name: "MLTX.US"
parent: "https://longbridge.com/zh-HK/quote/MLTX.US.md"
datetime: "2026-03-11T18:16:22.392Z"
locales:
  - [en](https://longbridge.com/en/quote/MLTX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/MLTX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/MLTX.US/news.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/MLTX.US/news.md) | [简体中文](https://longbridge.com/zh-CN/quote/MLTX.US/news.md)


# MLTX.US (MLTX.US) — 相關新聞

### [OSE narrows pipeline focus amid Boehringer MASH collaboration retreat](https://longbridge.com/zh-HK/news/277660319.md)
*2026-03-03T17:27:07.000Z*
> OSE Therapeutics is shifting its focus to late-stage development of its cancer vaccine, Tedopi, and anti-inflammatory dr

### [MoonLake Immunotherapeutics (MLTX) Is Down 6.3% After Wider 2025 Loss And SLK BLA Timeline Update – Has The Bull Case Changed?](https://longbridge.com/zh-HK/news/277529754.md)
*2026-03-02T22:51:42.000Z*
> MoonLake Immunotherapeutics (MLTX) shares fell 6.3% following a report of a wider net loss of $227.32 million for 2025, 

### [OSE Immunotherapeutics is focusing on advancing late stage value drivers Lusvertikimab and Tedopi with strategic refocusing.](https://longbridge.com/zh-HK/news/277501599.md)
*2026-03-02T17:01:48.000Z*
> OSE Immunotherapeutics is strategically refocusing on advancing its late-stage value drivers, Lusvertikimab and Tedopi®.

### [MoonLake Immunotherapeutics Investor Day: HS BLA on Track, axSpA Phase 2 Data Highlights Imaging Wins](https://longbridge.com/zh-HK/news/276690605.md)
*2026-02-24T06:16:19.000Z*
> MoonLake Immunotherapeutics (NASDAQ: MLTX) provided updates on its clinical portfolio during its Investor Day, highlight

### [MoonLake Immunotherapeutics (MLTX) Is Up 19.0% After Positive Phase 2 Axial Spondyloarthritis Data Release - Has The Bull Case Changed?](https://longbridge.com/zh-HK/news/276624558.md)
*2026-02-23T16:21:22.000Z*
> MoonLake Immunotherapeutics (MLTX) shares rose 19% following positive Phase 2 results for sonelokimab in treating axial 

### [MoonLake Immunotherapeutics' Spine Disease Treatment Shows Improvement in a Phase 2 Study](https://longbridge.com/zh-HK/news/276582079.md)
*2026-02-23T08:56:00.000Z*
> MoonLake Immunotherapeutics announced positive results from a Phase 2 clinical trial of its drug SLK for axial spondyloa

### [MoonLake announced positive topline results from Phase 2 trial of Sonelokimab in Axial Spondyloarthritis and reported 2025 financial results. Investor Day webcast scheduled for February 23, 2026.](https://longbridge.com/zh-HK/news/276539697.md)
*2026-02-22T16:01:13.000Z*
> MoonLake Immunotherapeutics announced positive topline results from its Phase 2 trial of Sonelokimab for Axial Spondyloa

### [MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results | MLTX Stock News](https://longbridge.com/zh-HK/news/276539336.md)
*2026-02-22T08:00:00.000Z*
> MoonLake Immunotherapeutics announced positive topline results from its Phase 2 S-OLARIS clinical trial of sonelokimab (